Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001968719 | SCV002255811 | likely pathogenic | Neurofibromatosis, type 1 | 2020-11-25 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Studies have shown that this variant is associated with exon 38 and 39 skipping, which introduces a frameshift (PMID: 27322474). The resulting mRNA is expected to undergo nonsense-mediated decay. This variant has been observed in individual(s) with neurofibromatosis, type 1 (PMID: 27322474). This variant is not present in population databases (ExAC no frequency). This sequence change falls in intron 36 of the NF1 gene. It does not directly change the encoded amino acid sequence of the NF1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. |
Baylor Genetics | RCV003471211 | SCV004190807 | likely pathogenic | Juvenile myelomonocytic leukemia | 2022-05-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004719213 | SCV005325653 | likely pathogenic | not provided | 2023-09-08 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect: patient-derived cDNA demonstrated two aberrant transcripts both leading to a frameshift and premature truncation (Evans et al., 2016); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27322474) |